DOMINO-HD study endorsed* by EHDN

Study aims and goal: Observational study funded by JPND (EU Joint Programme – Neurodegenerative Disease Research) assessing sleep, physical activity and nutrition in people with early-to-mid stage HD using digital technology e.g. wearable fitness trackers. No. of study participants and sites: approx. 300 participants for 12 months at 5 sites in Europe (UK, Germany, Spain, […]

Weiterlesen…

PROOF-HD study endorsed* by EHDN

Study aims and goal: An interventional, Phase III clinical trial to evaluate the efficacy and safety of pridopidine in patients with early stage manifest Huntington’s Disease (HD). No. of study participants and sites: The study aims to recruit 480 participants at sites in: Austria, Canada, Czech Republic, France, Germany, Italy, Netherlands, Poland, Spain, UK, USA […]

Weiterlesen…

VIBRANT-HD study endorsed* by EHDN

Study aims and goal: A Randomized, double-blind, placebo-controlled dose range finding study with Open-Label Extension to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LMI070/branaplam in participants with early manifest HD. No. of study sites: This Phase IIb study aims to recruit stage 1 and 2 participants at sites in Belgium, Canada, France, Germany, Hungary, […]

Weiterlesen…

Deep Brain Stimulation in HD

In December of this year, the last patient recruited into the European multi-centre deep brain stimulation study (HD-DBS) will reach the secondary endpoint (6 month follow-up). Recruitment was finished in 05/21. Perseverance pays off! The DBS team led by Professor Jan Vesper in Düsseldorf, Germany, expects data from the study to be available in 2022. […]

Weiterlesen…